1

Each page should be clearly numbered in the upper

Rama Med J | Original Article right corner; and should not exceed 15 pages.

Xxxxx ………………………………………………………Title should be in Angsana New, size 20, and bold.

Author names should be in Angsana New,
Xxx Xxxxx1, Xxx Xxxxx1, Xxx Xxxxxx2, Xxxx Xxxxxx3 size 18, and bold.

al
1
Department of ……………, Faculty of …………., …………….. University, Bangkok, Thailand Author affiliations should be in
Angsana New, size 14.

rn
2
Department of ……………, Faculty of …………., …………….. University, Surat Thani, Thailand
Please ensure that author
3
Center for ……………, School of ……………, …………… University, Scotland, UK affiliations are correct.

ou
Background: ……………………………………………………………... Corresponding Author:
…………………………………………………………………………..… Xxxxx Xxxxx
…………………………………………………………………………… Department of ……………….,

lJ
…….……………………………………………………………………… Faculty of …………………..,
Objective: ……………………………………………………………….... …………………... University,
…………………………………………………………………………..…
….…………………………………………………………………………. ica 00 ……….. Road, …….……..,
Bangkok 10400, Thailand.
ed
Methods: ………………………………………………………………...... Telephone: +66 XXXX XXXX
………………………………………………………………………...….. Fax: +66 XXXX XXXX
…….……………………………………………………………………… E-mail: ……………@………
M

……………………………………………………………………………. Corresponding author should

be provided full name and
…………………………………………………………………………… contact information.
di

Results: …………………………………………………………….…..…
bo

……………………………………………………………………..………
….…………………………………………………………………………
hi

…….………………………………………………………………………
………………………………………………………………………..……
at

….…………………………………………………………………………
m

Conclusions: ………………………………………………………………
…………………………………………………………………………… Manuscripts must be submitted both
English and Thai with an abstract
Ra

….………………………………………………………………………… limited to 250 words.

Keywords: …………………., …………………., …………………. Keywords should not exceed 6 words.

RMJ v.2/2019
 2

Introduction Study Design

…………………………………………… ……………………………………………
………………………………………………....... ……………………………………………….......
........................………………………………… ........................…………………………………
………………………………………………… …………………………………………………

al
………..................................…………………… ………...............................………………………

rn
………………………………………………… …………………………………………………
……………………...............................………… …………...............................……………………

ou
………………………………………………… …………………………………………………
………………………………............................... …………………………………………………
…………………………………………...………

lJ
…………………………………………………
…………………………………………............... ………………………………...............................
………………………………...............................
…………………………………………………
…………………………………………............... ica XX = XX + XX
Eq. 1
ed
Methods
Participants Xxxxxx Xxxxxx
…………………………………………… ……………………………………………
M

………………………………………………....... ………………………………………..……….....
........................………………………………… ..........................…………………………………
di

………………………………………………… …………………………………………………
………...............................……………………… ………...................………………………………
bo

………………………………………………… …………………………………………………
…………………..................... …………...............................
hi

Ethics Xxxxxx Xxxxxx

at

…....……(Reporting of informed consent ……………………………………………

………………………………………..……….....
m

and ethics committee approval)…………………

………… (approved by)……………………...… ..........................…………………………………
Ra

..…………….(from)……………………..……..... …………………………………………………
(No.).................., on ....... (date of approval)........ ………...................………………………………
………………………………………………..…. …………………………………………………
………………………………………………..…. …………...............................
………………………………………………..….

RMJ v.2/2019
 3

Statistical Analysis ........................………………………………...…

…………………………………………… ........................………………………………...…
………………………………………..………..... ........................………………………………...…
..........................………………………………… …………………………………………………...
………………………………………………… ...……………………………………………...…

al
………...................……………………………… ……………………………………………...........

rn
………………………………………………… ....................…………………………………...…
………………………………………………… ……………………………………………...……

ou
…………............................... ……...............................…………………………
………………………………………………...…
Results ………………...............................………………

……………………………………………
……………………………………………….......
........................………………………………...…
........................………………………………...…
ed
........................………………………………...…
........................………………………………...…
........................………………………………...…
M
lJ
………………...............................………………
………………………………………………...…
ica
………………...............................………………
………………………………………………...…
........................………………………………...…
........................………………………………...…
…………………………........................

Figure 1. Flow chart shows …………………………………………….

di

100 Xxx xxx ………………….

bo

…………………………..
hi
at

50 Xxx xxx ……………….. 27 Xxx xxx ………………..

m

20 Xxx xxx ……………….. 25 Xxx xxx ………………..

…………………………….. ……………………………..
Ra

30 Xxx xxx ……………….. 3 Xxx xxx ………………..

CAS indicates carotid stenting; XX, xxxxx xxxx; CEA, carotid endarterectomy.

RMJ v.2/2019
 4

Figure 2. Xxx Xxx …………………………………………….

A B

al
Figure, high-resolution printer at least

rn
300 dpi, should be embedded in the
text, and should also be submitted as
separate file. Figure should be

ou
numbered in the sequence in which
they are cited in the text.

lJ
ica
ed
A, XXxx Xxx …………………………………variation. B, …………………………variation.

Table should be numbered with Arabic numerals,

M

in the order in which they are cited in the text.

Table 1. Xxx Xxx ………………………………………………………………………… (N = 100)
Variable ………. (n = 45) ………. (n = 55) XXXX*
di

Sex
bo

Male
Female
Duration, mean, min
hi

Abbreviations: XX, xxxxx xxxxxxx; XX, xxxxx xxxxxxx; XX, xxxxx xxxxxxx.
*
The………was……………..
at

Table 2. Xxx Xxx ……………………………………………… (n = 50)

m

No. (%)
Factor
Ra

Total Yes No
Xxxxxxxx
Xxxxxxxx
Xxxxxxxx
Xxxxxxxx
Abbreviation: XX, xxxxx xxxxxxx.
RMJ v.2/2019
 5

Discussion Conclusions
…………………………………………… ……………………………………………
………………………………………………....... ……………………………………………….......
........................………………………………… ........................…………………………………
………………………………………………… …………………………………………………

al
………...............................……………………… ………...............................………………………

rn
………………………………………………… …………………………………………………
…………………...............................…………… …………………...............................……………

ou
………………………………………………… …………………………………………………
…………………………………........................... ……………………………...............................…

lJ
....……………………………………………… …………………………………………………
……………………………………………........... ………………………………………...................
....................……………………………………
…………………………………………………
……………………...............................………… ica
Acknowledgments (if any)
……………………………………………
ed
………………………………………………… ……………………………………………….......
………………………………............................... ........................…………………………………
………………………………………………… …………………………………………………
M

………………………………………………… ………..............................………………………
………………………………............................... …………………………………………………
di

…………………………………………………
………………………………………………… Disclosure (if any)
bo

………………………………............................... ……………………………………………
………………………………………………… ……………………………………………….......
hi

………………………………............................... ........................…………………………………
…………………………………………………
at

…………………………………………………
………………………………............................... ………...............................………………………
…………………………………………………
m

…………………………………………………
………………………………...............................
Ra

…………………………………………………
Xxxxxxxxxx (if any)
………………………………...............................
……………………………………………
…………………………………………………
……………………………………………….......
………………………………...............................
........................…………………………………
…………………………………………………
………………………………………………
RMJ v.2/2019
 6

References
1. Xxx X, Xxx X. Xxxxxxxxxx 3. Xxx X, Xxx X, Xxx X, 5. Xxxxxxxxxxx. Xxxxxxxxxx.
xxxxxxxxxx xxxxxxxxxxxxx. et al. Xxxxxxxxxxxxxxxxxx. http://www.cccc/ccccccc.htm.
J Xxxx Xxx. YYYY;VV(SS): xxxxxxxxxx xxxxxxxxxxxxx. Updated MM DD, YYYY.
P12-P28. J Xxxx Xxx. YYYY;VV(SS): Accessed MM DD, YYYY.

al
2. Xxx X, Xxx X, Xxx X, 18-25. 6. Xxx Xx. Xxxxxxx Xxxxxxx

rn
Xxx X, Xxx X, Xxx X. 4. Xxx Xx. Xxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx
Xxxxxxxxxx xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxxxxx [dissertation].

ou
xxxxxxxxxx xxxxxxx xxxxx. Xxxxxxx [master’s thesis]. Sweden: Xxxxxx University.
J Xxxx Xxx. YYYY;VV(SS): Birmingham: Xxx University. YYYY.
113-115. doi:xxxxxxxxxxxx. YYYY.

lJ
Our journal requires to use AMA
Citation Style, and only the English
alphabet in the reference list.
Number of references should not

ica
exceed 25-30. Citing secondary
resources such as review articles or
textbooks should be avoided.
ed
M
di
bo
hi
at
m
Ra

RMJ v.2/2019
 7

Rama Med J | Original Article

Xxxxx ………………………………………………………Title should be in Angsana New, size 20, and bold.

Author names should be in Angsana New,
Xxx Xxxxx1, Xxx Xxxxx1, Xxx Xxxxxx2, Xxxx Xxxxxx3 size 18, and bold.

al
1
ภาควิชา…………… คณะ………….…………. มหาวิทยาลัย..................... กรุงเทพฯ ประเทศไทย Author affiliations should be in
ภาควิชา…………… คณะ………….…………. มหาวิทยาลัย..................... สุราษฎร์ธานี ประเทศไทยAngsana New, size 14.

rn
2
Please ensure that author
3
Center for ……………, School of ……………, …………… สกอตแลนด์ ประเทศสหราชอาณาจักร affiliations are correct.

ou
บทน ำ: ………………………..…………………………………………... Corresponding Author:
…………………………………………………………………………..… .............ชื่อ นามสกุล…………
…………………………………………………………………………… ภาควิชา...........................................

…….………………………………………………………………………
วัตถุประสงค์: …………………………………………………………….
…………………………………………………………………………..…
….………………………………………………………………………….
ed
วิธีกำรศึกษำ: ……………………………………………………………….
………………………………………………………………………...…..
…….………………………………………………………………………
M
lJ
คณะ.................................................
มหาวิทยาลัย..................................
ica 000 ถนน.........................................
แขวง................................................
เขต...................................................
กรุงเทพฯ 10400 ประเทศไทย
โทรศัพท์ +66 XXXX XXXX

……………………………………………………………………………. โทรสาร +66 XXXX XXXX

…………………………………………………………………………… อีเมล ……………@...........
di

ผลกำรศึกษำ: ……………………………………………………………… Corresponding author should

be provided full name and
……………………………………………………………………..………
bo

contact information.
….…………………………………………………………………………
…….………………………………………………………………………
hi

………………………………………………………………………..……
….…………………………………………………………………………
at

สรุป: …………………………………………….…………………………
m

………………………………………………………………………..……
Manuscripts must be submitted both
….………………………………………………………………………… English and Thai with an abstract
limited to 250 words.
Ra

คำสำคัญ: …………………. …………………. …………………. Keywords should not exceed 6 words.

RMJ v.2/2019